Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomised, Parallel Group Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Relvar/Breo ELLIPTA Therapy, in Asthmatic Subjects With Poor Control

NCT03380429 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03380429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03380429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomised, Parallel Group Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Relvar/Breo ELLIPTA Therapy, in Asthmatic Subjects With Poor Control
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2018
Completion date
January 24, 2019
Enrollment
437 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

asthma